ITI MF

CATEGORY OF SCHEME	Sectoral/Thematic
INVESTMENT OBJECTIVE	The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. However, there can be no assurance that the investment objective of the scheme would be achieved.
Inception Date (Date of Allotment):	08-Nov-21
Benchmark:	Nifty Healthcare TRI
Minimum Application Amount:	Rs.5,000/- and in multiples of Rs. 1/- thereafter
Load Structure:	Entry Load: Nil Exit Load: 1% if redeemed or switched out on or before completion of 12 months from the date of allotment of units · Nil, if redeemed or switched out after completion of 12 months from the date of allotment of units.
Total Expense Ratio (TER):	Including Additional Expenses and Goods and Service Tax on Management Fees Regular Plan: 2.35% Direct Plan: 0.47%
Fund Manager	Mr. Rohan Korde (Since 08-Nov-21) Total Experience: 17 years Mr. Dhimant Shah (Since 01 December 2022) Total Experience : 26 years

AUM (in Rs. Cr):	213.77
AAUM (in Rs. Cr):	207.19
% of top 5 holdings:	38.51%
% of top 10 holdings:	57.22%
No. of scrips:	39

Standard Deviation^:	16.40%
Beta^:	0.91
*Sharpe Ratio^:**	0.66
Average P/B	9.65
Average P/E	45.60
Portfolio Turnover Ratio	0.61
^Computed for the 3-yr period ended March 31, 2025. Based on monthly return. * Risk free rate: 7.20 (Source: FIMMDA MIBOR)

	Regular Plan (in Rs.)	Direct Plan (in Rs.)
Growth:	15.6470	16.7703
IDCW:	15.6470	16.7703

Name of the Instrument	% to NAV	% to NAV Derivatives
Equity & Equity Related Total	97.95
Chemicals	4.37
Sumitomo Chemical India Limited	1.52
SRF Limited	0.98
UPL Limited	0.95
Linde India Limited	0.92
Healthcare	93.58
Sun Pharmaceutical Industries Limited	16.22
Divi's Laboratories Limited	5.96
Lupin Limited	5.78
Suven Pharmaceuticals Limited	5.39
Apollo Hospitals Enterprise Limited	5.16
Max Healthcare Institute Limited	5.07
Torrent Pharmaceuticals Limited	4.11
Aurobindo Pharma Limited	3.61
Mankind Pharma Limited	3.09
Alkem Laboratories Limited	2.84
Aster DM Healthcare Limited	2.81
Abbott India Limited	2.43
Neuland Laboratories Limited	2.28
Granules India Limited	1.99
Dr. Reddy's Laboratories Limited	1.91
Wockhardt Limited	1.90
Healthcare Global Enterprises Limited	1.72
Supriya Lifescience Limited	1.71
Fortis Healthcare Limited	1.56
FDC Limited	1.44
GlaxoSmithKline Pharmaceuticals Limited	1.39
Rainbow Childrens Medicare Limited	1.32
Orchid Pharma Limited	1.32
Caplin Point Laboratories Limited	1.24
JB Chemicals & Pharmaceuticals Limited	1.23
Gland Pharma Limited	1.22
Emcure Pharmaceuticals Limited	1.17
Sai Life Sciences Limited	1.06
Vijaya Diagnostic Centre Limited	1.05
Cipla Limited	1.04
Onesource Specialty Pharma Limited	1.03
Shilpa Medicare Limited	1.02
Sequent Scientific Limited	0.91
Strides Pharma Science Limited	0.86
Laurus Labs Limited	0.74
Short Term Debt & Net Current Assets	2.05

Top Ten Holdings

Period	Fund Returns (%)	Benchmark Returns (%)	Additional Benchmark Returns (%)	Benchmark (Rs)	Fund (Rs)	Additional Benchmark Returns (Rs)
Regular - Growth
Last 1 Year	15.65%	14.10%	6.65%	11,565	11,410	10,665
Last 3 Years	18.06%	18.17%	11.77%	16,442	16,486	13,956
Since Inception	14.13%	15.34%	9.33%	15,647	16,216	13,528
Direct - Growth
Last 1 Year	17.84%	14.10%	6.65%	11,784	11,410	10,665
Last 3 Years	20.47%	18.17%	11.77%	17,466	16,486	13,956
Since Inception	16.50%	15.34%	9.33%	16,770	16,216	13,528

Past performance may or may not be sustained in future and is not a guarantee of any future returns, and should not be used as a basis of comparison with other investments. In case, the start / end date of the concerned period is a non-business date (NBD), the NAV of the previous date is considered for computation of returns. Different Plans i.e. Regular Plan and Direct Plan under the scheme have different expense structure. Benchmark: Nifty Healthcare TRI Additional Benchmark: Nifty 50 TRI. Fund Managers: Mr. Rohan Korde (Managing since 08-Nov-21) and Mr. Dhimant Shah (Managing since 01-December-22). Inception date of the scheme is (08-Nov-2021). Face Value per unit: Rs. 10. Since the scheme is in existence for more than 3 years but less than 5 years hence performance data for 5 years and more are not provided.
Since the scheme is in existence for more than 3 years but less than 5 years hence performance data for 5 years and more are not provided.
ITI Pharma & Healthcare Fund NAV as on March 28, 2025: Rs. 15.6470 (Regular Growth Option), Rs. 16.7703 (Direct Growth Option)

Period	Amount Invested	Fund Returns (%)	Benchmark Returns (%)	Additional Benchmark Returns (%)	Fund Value ()	Benchmark Value ()	Additional Benchmark Value ()
Regular - Growth
Last 1 Year	1,20,000	3.59%	4.74%	-1.15%	1,22,258	1,22,971	1,19,270
Last 3 Years	3,60,000	22.48%	23.71%	12.35%	4,98,496	5,07,012	4,32,382
Since Inception	4,10,000	20.72%	21.88%	12.03%	5,78,553	5,89,273	5,02,566
Direct - Growth
Last 1 Year	1,20,000	5.60%	4.74%	-1.15%	1,23,510	1,22,971	1,19,270
Last3 Years	3,60,000	24.92%	23.71%	12.35%	5,15,401	5,07,012	4,32,382
Since Inception	4,10,000	23.12%	21.88%	12.03%	6,00,900	5,89,273	5,02,566

Past performance may or may not be sustained in future and is not a guarantee of any future returns, and should not be used as a basis of comparison with other investments. Different Plans i.e. Regular Plan and Direct Plan under the scheme have different expense structure. Benchmark: Nifty Healthcare TRI Additional Benchmark: Nifty 50 TRI. For SIP returns, monthly investment of Rs.10,000 invested on the 1st business day of every month has been considered. CAGR Returns (%) are computed after accounting for the cash flow by using the XIRR method (investment internal rate of return).